Introduction
Materials and methods
Study group
Control group
Brain CT and CTA examinations
Study group brain CT assessment
Assessment of the supra-aortic arteries and the CoW
Reproducibility of CTA
Statistical analysis
Results
Characteristics of the study and control groups
Study group (N=544) | Control group (N=196) | p-value | |
---|---|---|---|
Demographics
| |||
Male gender | 331 (61%) | 117 (60%) | 0.777 |
Mean age ± SD (years) | 69 ± 8 | 66±11 | <0.001 |
Symptomatic | 205 (38%) | - | - |
Cardiovascular risk factors, N (%)
|
Data available in 173 patients
| ||
Hypertension | 500 (92%) | 110 (64%) | <0.001 |
Cigarette smoking | 175 (32%) | 16 (9%) | <0.001 |
Hyperlipidemia | 234 (43%) | 49 (28%) | 0.001 |
Coronary artery disease | 170 (31%) | 30 (17%) | <0.001 |
Chronic pulmonary disease | 53 (10%) | 13 (8%) | 0.377 |
Chronic kidney disease (Stage IIIb-V) | 16 (3%) | 6 (3%) | 0.726 |
Diabetes | 203 (37%) | 32 (18%) | <0.001 |
Carotid artery stenosis, N (%)
| |||
<70% on both sides (Score 0) | 3 (0.6%) | - | - |
70–89% on the side of surgery (Score 1) | 128 (23.5%) | - | - |
70–89% on both sides (Score 2) | 26 (4.8%) | - | - |
90–99% on the side of surgery (Score 2) | 282 (51.7%) | - | - |
90–99% on the side of surgery + 70–89% on the contralateral side (Score 3) | 54 (9.9%) | - | - |
90–99% on both sides (Score 4) or 70–89% on the side of surgery + contralateral occlusion (Score 4) or 90–99% on the side of surgery + contralateral occlusion (Score 5) | 51 (9.4%) | - | - |
CoW groups N (%)
| |||
Group I) | 78 (14%) | 55 (28%) | <0.001 |
Group II) | 97 (18%) | 52 (27%) | |
Group III) | 191 (35%) | 55 (28%) | |
Group IV) | 178 (33%) | 34 (17%) |
Study group analysis
Group I) Complete CoW or 1 hypoplastic segment | Group II) ≥2 hypoplastic segments | Group III) 1 non-visualized segment | Group IV) ≥2 non-visualized segments | p-value | |
---|---|---|---|---|---|
Demographics
| (n = 78) | (n = 97) | (n = 191) | (n = 178) | |
Male gender | 48 (61.5%) | 51 (52.6%) | 121 (63.4%) | 111 (62.4%) | 0.324 |
Age ± SD (years) | 68 ± 9 | 67 ± 8 | 69 ± 8 | 70 ± 8 | 0.107 |
Symptomatic | 21 (26.9%) | 38 (39.2%) | 68 (35.6%) | 78 (43.8%) | 0.067 |
Cardiovascular risk factors, N (%)
| |||||
Hypertension | 70 (89.7%) | 89 (91.8%) | 175 (91.6%) | 166 (93.2%) | 0.813 |
Cigarette smoking | 26 (33.3%) | 39 (40.2%) | 73 (38.2%) | 37 (20.8%) | 0.001 |
Hyperlipidemia | 41 (47.5%) | 41 (42.3%) | 77 (40.3%) | 75 (43.9%) | 0.315 |
Coronary artery disease | 34 (43.6%) | 31 (32.0%) | 52 (27.2%) | 53 (29.8%) | 0.067 |
Chronic pulmonary disease | 9 (8.9%) | 14 (14.4%) | 19 (9.9%) | 11 (7.1%) | 0.290 |
Chronic kidney disease (Stage IIIb to V) | 2 (2.0%) | 5 (5.2%) | 4 (2.1%) | 5 (3.2%) | 0.472 |
Diabetes | 26 (31.7%) | 36 (37.1%) | 69 (36.1%) | 72 (42.3%) | 0.707 |
ICA stenosis, N (%)
| |||||
<70% on both sides (Score 0) | 0 (1.0%) | 0 (0.0%) | 0 (0.0%) | 3 (1.3%) | 0.010 |
70–89% on the side of surgery (Score 1) | 13 (20.8%) | 20 (20.6%) | 52 (27.2%) | 43 (22.6%) | |
70–89% on both sides (Score 2) | 5 (5.9%) | 3 (3.1%) | 8 (4.2%) | 10 (5.8%) | |
90–99% on the side of surgery (Score 2) | 35 (43.6%) | 59 (60.8%) | 94 (49.2%) | 94 (54.8%) | |
90–99% on the side of surgery + 70–89% on the contralateral side (Score 3) | 12 (13.9%) | 5 (5.2%) | 14 (7.3%) | 23 (13.5%) | |
90–99% on both sides (Score 4) or 70–89% on the side of surgery + contralateral occlusion (Score 4) or 90–99% on the side of surgery + contralateral occlusion (Score 5) | 13 (14.9%) | 10 (10.3%) | 23 (12.0%) | 5 (1.9%) | |
Brain CT N (%) | |||||
Negative 398 (73%) | 61 (15%) | 74 (19%) | 151 (38%) | 112 (28%) | 0.002* |
Positive 146 (27%) | 19 (13%) | 24 (16%) | 42 (29%) | 61 (42%) |
Segment/Circle | STUDY GROUP (N=544) | CONTROL GROUP (N=196) | p* | |||||
---|---|---|---|---|---|---|---|---|
Normal | Hypoplasia | Non-visualization | Normal | Hypoplasia | Non-visualization | |||
AComA (N)
| All | 369 (67.8%) | 154 (28.3%) | 21 (3.9%) | 155 (79.1 %) | 40 (20.4%) | 1 (0.5%) | 0.003 |
Single variant | N/A | 9 (1.7%) | 2 (0.4%) | |||||
Combined variant | N/A | 145 (26.7%) | 19 (3.5%) | |||||
A1
(N x 2)
| All | 964 (88.6%) | 81 (7.4%) | 43 (4.0%) | 380 (97.0%) | 8 (2.0%) | 4 (1.0%) | <0.001 |
Single variant | N/A | 6 (0.6%) | 2 (0.2%) | |||||
Combined variant | N/A | 75 (6.9%) | 41 (3.8%) | |||||
PComA
(N x 2)
| All | 366 (33.6%) | 275 (25.3%) | 447 (41.1%) | 161 (41.1%) | 121 (30.9%) | 110 (28.0%) | 0.008 |
Single variant | N/A | 36 (3.3%) | 26 (2.4%) | |||||
Combined variant | N/A | 239 (22.0%) | 421 (38.7%) | |||||
P1
(N x 2)
| All | 948 (87.1%) | 81 (7.4%) | 59 (5.4%) | 354 (90.3%) | 33 (8.4%) | 5 (1.3%) | 0.098 |
Single variant | N/A | 6 (0.6%) | 2 (0.2%) | |||||
Combined variant | N/A | 75 (6.9%) | 57 (5.2%) | |||||
Anterior CoW
(N)
| All | 257 (47.2%) | 223 (41.0) | 64 (11.8%) | 143 (73.0%) | 48 (24.5%) | 5 (2.5%) | <0.001 |
Complete posterior part | 19 (3.5%) | 198 (4.5%) | 60 (11.0%) | |||||
Posterior part variant | 238 (43.8%) | 25 (36.4%) | 4 (0.7%) | |||||
Posterior CoW
(N x 2)
| All | 234 (21.9%) | 351 (32.2%) | 503 (46.2%) | 123 (31.4%) | 154 (39.3%) | 115 (29.3%) | <0.001 |
Complete anterior part | 38 (3.5%) | 182 (16.5%) | 226 (20.8%) | |||||
Anterior part variant | 196 (18.0%) | 169 (15.5%) | 277 (25.5%) |
Segment/circle | Autopsy studies | Imaging studies | Present Study | |||
---|---|---|---|---|---|---|
Controls | Study group | Controls | Study group | |||
AComA
| Non-visualization | 0–3.2% | 1–19% | 4–40% | 3.9% | 0.5% |
hypoplasia | 3–32% | 23% [29] | 4–11% | 28.3% | 20.4% | |
A1
| Non-visualization | 0–0.8% | 1–7% | 4–15% | 4.0% | 1.0% |
hypoplasia | 1.5–7.5% | 4–10% | 8–24% | 7.4% | 2.0% | |
PComA
| Non-visualization | 0–3.5% | 22–38% | 21–66% | 41.1% | 28.0% |
hypoplasia | 23–70% | 38–41% | 6–18% | 25.3% | 30.9% | |
P1
| Non-visualization | 0–2.4% | 0–2% | 3–10% | 5.4% | 1.3% |
hypoplasia | 12–23% | 3–6% | 1–8% | 7.4% | 8.4% | |
Anterior CoW
| incomplete | - | 2–12% | 12–24% | 11.8% | 2.5% |
hypoplastic | - | 4–10% | 17% | 41.0% | 24.5% | |
Posterior CoW
| incomplete | - | 23–39% | 37–74% | 46.2% | 29.3% |
hypoplastic | - | 29% [28] | 15–40% | 32.2% | 39.3% |
Both posterior CoWs | Anterior CoW | ||||||
---|---|---|---|---|---|---|---|
complete | AComA hypoplasia | AComA non-visualization | A1 hypoplasia | A1 non-visualization | Total | ||
As a whole | complete | 19 (3.5%) | 9 (1.7%) | 2 (0.4%) | 7 (1.3%) | 2 (0.4%) | 39 (7.3%) |
PComA | unilateral hypoplasia | 35 (6.4%) | 12 (2.2%) | 0 | 12 (2.2%) | 5 (0.9%) | 64 (11.7%) |
unilateral non-visualization | 26 (4.8%) | 20 (3.7%) | 2 (0.4%) | 10 (1.8%) | 9 (1.7%) | 67 (12.3%) | |
bilateral hypoplasia | 25 (4.6%) | 9 (1.7%) | 1 (0.2%) | 8 (1.5%) | 3 (0.6%) | 46 (8.4%) | |
bilateral non-visualization | 44 (8.1%) | 39 (7.2%) | 10 (1.8%) | 19 (3.4%) | 6 (1.1%) | 118 (21.7%) | |
non-visualization - contralateral hypoplasia | 46 (8.4%) | 27 (5.0%) | 1 (0.2%) | 11 (2.0%) | 8 (1.5%) | 93 (17.1%) | |
PComA-P1 | PComA hypoplasia - contralateral P1 hypoplasia | 6 (1.1%) | 4 (0.7%) | 0 | 2 (0.4%) | 1 (0.2%) | 13 (2.4%) |
PComA and contralateral P1 non-visualization | 13 (2.4%) | 6 (1.1%) | 0 | 1 (0.2%) | 2 (0.4%) | 22 (4.0%) | |
PcomA hypoplasia - contralateral P1 non-visualization | 7 (1.3%) | 1 (0.2%) | 0 | 0 | 2 (0.4%) | 10 (1.8%) | |
PcomA non-visualization - contralateral P1 hypoplasia | 13 (2.4%) | 5 (0.9%) | 2 (0.4%) | 2 (0.4%) | 0 | 22 (4.0%) | |
P1 | unilateral hypoplasia | 7 (1.3%) | 5 (0.9%) | 0 | 7 (1.3%) | 1 (0.2%) | 20 (3.7%) |
unilateral non-visualization | 2 (0.4%) | 0 | 1 (0.2%) | 1 (0.2%) | 1 (0.2%) | 5 (0.9%) | |
bilateral hypoplasia | 2 (0.4%) | 2 (0.4%) | 0 | 0 | 1 (0.2%) | 5 (0.9%) | |
bilateral non-visualization | 3 (0.6%) | 0 | 1 (0.2%) | 0 | 1 (0.2%) | 5 (0.9%) | |
non-visualization - contralateral hypoplasia | 6 (1.1%) | 2 (0.4%) | 0 | 0 | 1 (0.2%) | 9 (1.7%) | |
Other | multiple hypoplasia and/or non-visualization | 3 (0.6%) | 2 (0.4%) | 1 (0.2%) | 0 | 0 | 6 (1.1%) |
Total | 257 (47.0%) | 143 (26.5%)* | 21 (3.9%) | 80 (14.7%) | 43 (8.0%) | 544 (100%) |